Stage at diagnosis and survival by stage for the leading childhood cancers in Rwanda

Abstract

AbstractBackgroundThe lack of accurate population‐based information on childhood cancer stage and survival in low‐income countries is a barrier to improving childhood cancer outcomes.MethodsIn this study, data from the Rwanda National Cancer Registry (RNCR) were examined for children aged 0–14 diagnosed in 2013–2017 for the eight most commonly occurring childhood cancers: acute lymphoblastic leukaemia, Hodgkin lymphoma (HL), Burkitt lymphoma (BL), non‐Hodgkin lymphoma excluding BL, retinoblastoma, Wilms tumour, osteosarcoma and rhabdomyosarcoma. Utilising the Toronto Childhood Cancer Stage Guidelines Tier 1, the study assigned stage at diagnosis to all, except HL, and conducted active follow‐ups to calculate 1‐, 3‐ and 5‐year observed and relative survival by cancer type and stage at diagnosis.ResultsThe cohort comprised 412 children, of whom 49% (n = 202) died within 5 years of diagnosis. Five‐year survival ranged from 28% (95% confidence interval [CI]: 12.5%–45.6%) for BL to 68% (CI: 55%–78%) for retinoblastoma. For the cancers for which staging was carried out, it was assigned for 83% patients (n = 301 of 362), with over half (58%) having limited or localised stage at diagnosis. Stage was a strong predictor of survival; for example, 3‐year survival was 70% (95% CI: 45.1%–85.3%) and 11.8% (2.0%–31.2%) for limited and advanced non‐HL, respectively (p < .001).ConclusionThis study is only the second to report on stage distribution and stage‐specific survival for childhood cancers in sub‐Saharan Africa. It demonstrates the feasibility of the Toronto Stage Guidelines in a low‐resource setting, and highlights the value of population‐based cancer registries in aiding our understanding of the poor outcomes experienced by this population.